for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SINOPHARM HOLDING CO LTD

1099.HK

Latest Trade

19.16HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

14.70

 - 

29.70

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
19.16
Open
--
Volume
--
3M AVG Volume
257.83
Today's High
--
Today's Low
--
52 Week High
29.70
52 Week Low
14.70
Shares Out (MIL)
3,120.66
Market Cap (MIL)
59,292.47
Forward P/E
7.51
Dividend (Yield %)
3.43

Next Event

Half Year 2020 SINOPHARM GROUP CO LTD Earnings Release

Latest Developments

More

Sinopharm Group Says Entered Procurement Framework Agreement With Natong Group Co

Sinopharm Group Announces Acquisition Of Chengda Fangyuan By Guoda Drugstores

Sinopharm Group Says Will Form JV Co With CNBG, Guangdong Medi-World & Others

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SINOPHARM HOLDING CO LTD

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments. The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics. The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products. The Company is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

No. 1001 Zhongshan West Road

SHANGHAI, SHA

200051

China

+86.21.23052666

http://www.sinopharmgroup.com.cn/

Executive Leadership

Zhiming Li

Executive Chairman of the Board and Deputy Secretary of Party Committee

Yong Liu

President, Executive Director

Qiyu Chen

Non-Executive Vice Chairman of the Board

Xiuchang Jiang

Chief Financial Officer, Vice President

Maisong Cai

Vice President

Key Stats

2.05 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

277.7K

2018

344.5K

2019

425.3K

2020(E)

464.2K
EPS (CNY)

2017

1.910

2018

1.960

2019

2.100

2020(E)

2.185
Price To Earnings (TTM)
8.13
Price To Sales (TTM)
0.13
Price To Book (MRQ)
1.07
Price To Cash Flow (TTM)
4.31
Total Debt To Equity (MRQ)
116.27
LT Debt To Equity (MRQ)
24.19
Return on Investment (TTM)
18.93
Return on Equity (TTM)
4.20

Latest News

Latest News

China's Sinopharm says coronavirus vaccine could be ready by year-end - state media

A coronavirus vaccine candidate developed by China National Pharmaceutical Group (Sinopharm) could be ready for public use by the end of this year, state media reported on Wednesday, ahead of a previous expectation it may become available in 2021.

China's Sinopharm begins late stage trial of COVID-19 vaccine in UAE

Chinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Abu Dhabi using up to 15,000 volunteers, the government in the capital of the United Arab Emirates said on Thursday.

Sinopharm COVID-19 vaccine phase 3 trial begins in Abu Dhabi

Chinese state-owned pharmaceutical company Sinopharm has begun phase 3 clinical trials of a COVID-19 vaccine in the emirate of Abu Dhabi, the Abu Dhabi government media office said on Thursday.

BRIEF-Sinopharm Group Says Will Form JV Co With CNBG, Guangdong Medi-World & Others

* ENTERED JV AGREEMENT WITH CHINA NATIONAL PHARMACEUTICAL GROUP

China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacity

China National Biotec Group (CNBG) said on Wednesday it has completed construction of a new plant for coronavirus vaccines, doubling its capacity to more than 200 million doses a year, as it prepares late-stage trials of its potential COVID-19 shots.

BRIEF-Masterwork Group In Strategic Agreement With Sinopharm's Testing Arm

* SAYS IT SIGNS STRATEGIC AGREEMENT WITH SINOPHARM GROUP CO LTD'S TESTING ARM ON PRODUCTION OF MEDICAL PROTECTION GEAR Source text in Chinese: https://bit.ly/2MMayle Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Sinopharm Group Posts Qtrly Total Operating Revenue RMB94.40 Bln

* QTRLY TOTAL OPERATING REVENUE RMB94.40 BILLION VERSUS RMB95.18 BILLION

BRIEF-Shanghai Henlius Biotech Says Agreed That Sinopharm Group Will Be One Of Distributors Of Certain Products

* AGREED THAT SINOPHARM GROUP WILL BE ONE OF DISTRIBUTORS OF CERTAIN OF GROUP'S BIOPHARMACEUTICAL PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Sinopharm Group Posts FY Operating Income RMB 52.05 Billion

* SINOPHARM GROUP CO LTD- FY OPERATING INCOME RMB 52.05 BILLION VERSUS RMB 43.12 BILLION

BRIEF-Giglio Group Signs Framework Agreement With Sinopharm For Import And Export Of Medical Products From And To China

* SIGNS FRAMEWORK AGREEMENT WITH SINOPHARM FOR IMPORT AND EXPORT OF SANITARY PRODUCTS, FROM AND TO CHINA

BRIEF-Sinopharm Group Proposes Issuance Of Corporate Bonds In PRC

* SINOPHARM GROUP CO LTD PROPOSES ISSUE OF CORPORATE BONDS IN PRC

BRIEF-Sinopharm Group Sees Significant Decline In Q1 Performance

* ANTICIPATES GROUP'S PERFORMANCE FOR Q1 ENDING 31 MARCH 2020 MAY DECLINE SIGNIFICANTLY ON A YEAR-ON-YEAR BASIS

HK-listed Sinopharm plans $524 million share sale to expand distribution network

China's pharmaceutical products distributor Sinopharm Group Co Ltd <1099.HK> said on Friday it plans to issue HK$4.07 billion ($523.66 million) worth of H shares to raise capital for the expansion of its distribution and retail network.

Sinopharm buys 60 pct device distributor for $765 mln

Pharmaceutical products distributor Sinopharm Group Co Ltd said late on Wednesday it would buy 60 percent of a medical devices distributor from the controlling parent company for 5.11 billion yuan ($765.4 million), as it aims to expand market share in its medical device...

BRIEF-Sinopharm Group Posts Qtrly Net Profit Attributable RMB842.7 Million

* QTRLY TOTAL OPERATING REVENUE RMB72.69 BILLION VERSUS RMB68.42 BILLION

BRIEF-Sinopharm Group Co Expects Q1 Net Profit Attributable Down About 30%

* EXPECTS Q1 NET PROFIT ATTRIBUTABLE TO RECORD DECLINE OF ABOUT 30%

BRIEF-Sinopharm Group Co Posts ‍FY Profit Of RMB5.28 Bln

* FY PROFIT ATTRIBUTABLE RMB 5.28 BILLION VERSUS RMB 4.65 BILLION Source text for Eikon: Further company coverage:

BRIEF-Sinopharm Group Co's Board Resolves To Propose Issue Of Corporate Bonds In China

* BOARD RESOLVED TO PROPOSE ISSUE OF CORPORATE BONDS IN PRC; ISSUE SIZE OF NO MORE THAN RMB10 BILLION Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Sinopharm Group posts ‍9-mnth profit attributable of RMB ‍3.66​ billion​

* 9-month net profit attributable to equity holders of co RMB 3.66 billion versus RMB3.60 billion

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up